Stroke Prevention With Oral Anticoagulation Therapy in Patients With Atrial Fibrillation

Lip, Gregory Y. H.; Lane, Deirdre A.

doi:10.1253/circj.cj-13-0465

Cited by 37 publications

(25 citation statements)

References 57 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, patients ≥85 years of age were less likely to receive OAC ( Figure 1B, Table 2), although the use of OAC in these patients is always a matter of debate. 16 These data indicate discordance between the guidelines and "real-world" clinical practice, and identification of patients perceived to be at risk of stroke is often not based on evidence-based risk schemes and guidelines.…”

Section: Oac Underuse For Patients At Riskmentioning

confidence: 99%

Inappropriate Use of Oral Anticoagulants for Patients With Atrial Fibrillation

Akao

Yuan

Esato

et al. 2014

Circ J

127

View full text Add to dashboard Cite

Section: Oac Underuse For Patients At Riskmentioning

confidence: 99%

Inappropriate Use of Oral Anticoagulants for Patients With Atrial Fibrillation

Akao

Yuan

Esato

et al. 2014

Circ J

127

View full text Add to dashboard Cite

“…During the cerebral ischemia progression, oral administration of anticoagulation is recommended as a choice of therapy for both primary and secondary ischemic stroke prevention in patients with atrial fibrillation or any other risk factors (Lip and Lane, 2013;Toth, 2013). Therefore, it is interesting to know if Xinnaoning has any anti-coagulation effect which may benefit ischemic stroke prevention.…”

Section: Xinnaoning Has Anti-coagulation Effectmentioning

confidence: 99%

Protective Role of Xinnaoning Tablet in Ischemic Stroke in Rat Model

Lv¹,

Xie²,

Feng³

et al. 2018

AJTCAM

View full text Add to dashboard Cite

Background: Stroke has been considered as the second leading cause of death worldwide. The survivors of stroke experience different level of impair brain function. In China, Chinese traditional medicine had been widely accepted for stroke therapy and prevention. In this study, we developed Traditional Chinese Medicine based Xinnaoning (peace of heart and brain) Tablet and tested its protective role for ischemic stroke in rat model. Material and Methods: Male Wistar rats (n=60) with 12 weeks old and weight from 180 to 200 gram were randomly divided to five groups (n=12). For the groups with Xinaoning administration, the drug was administrated to rats once per day for 7 consecutive days. The blood clotting time and the thrombus wet weight was measured. Serum samples were collected from each rat for further Measurement of biochemical indicators. Results: Our results demonstrated that Xinnaoning tablet reduced lactate acid (LD) level and increased lactic acid dehydrogenase (LDH) in cerebral ischemia model as well as reduced the infarct size caused by stroke. Besides, evaluation of the level of different ATPases suggested Xinnaoning tablet could modulate ATPases activity and confer a protective role in brain. Moreover, analysis indicated Xinnaoning tablet have the anti-coagulation effect in vivo which may contribute to the protection of ischemia. Conclusion: Our findings suggest that Xinnaoning tablet may be a potential way for cerebral ischemia prevention.

show abstract

“…Ce soustraitement évalué à 50 % par Tavassoli et al [13] trouverait une explication selon Choudhry et al [14] dans la crainte d'une surestimation du risque hémorragique par les prescripteurs. Il s'agit pour Lip et Lane [15] d'une conception paradoxale car pour eux la prescription d'anticoagulants est associée à un bénéfice/risque favorable chez la personne âgée.…”

Section: Justification D'un Protocole En Ehpadunclassified